Bayer AG annual free cash flow
2022
2023
2024
2025
Bayer AG Free Cash Flow (FCF) History (BAYN)
Bayer AG reported €3.44B in free cash flow for fiscal 2025, a decrease of 24.99% from the previous fiscal year, with a free cash flow margin of 7.55%.
View full Bayer AG company overviewBayer AG free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | €3.44B | −€1.15B | −24.99% | +7.55% |
| 2024 | 2024-12-31 | €4.59B | €2.22B | +94.00% | +9.85% |
| 2023 | 2023-12-31 | €2.37B | −€1.78B | −42.91% | +4.97% |
| 2022 | 2022-12-31 | €4.14B | — | — | +8.17% |
Bayer AG quarterly free cash flow
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €30.0M | −€563.0M | −94.94% | +0.28% |
| Q1 2026 | 2026-03-31 | −€2.21B | — | — | −16.45% |
| Q4 2025 | 2025-12-31 | €3.40B | — | — | +29.76% |
| Q3 2025 | 2025-09-30 | €849.0M | — | — | +8.79% |
| Q2 2025 | 2025-06-30 | €593.0M | — | — | +5.52% |
Bayer AG free cash flow growth trends
Bayer AG's latest reported quarter, Q2 2026, generated €30.0M in free cash flow, a decrease of 94.94% year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Bayer AG source filings ↗Community posts
Bayer wins the first Roundup trial following the Supreme Court ruling
A Missouri jury unanimously ruled for Bayer ($BAYN)’s Monsanto unit in a three-plaintiff Roundup case, rejecting design-defect, fraud and negligence claims. It was the first such trial following the US Supreme Court decision that blocked th ...
Bayer’s Nubeqa cuts risk of metastasis or death in prostate trial
Bayer ($BAYN) disclosed interim Phase 3 results showing that adding Nubeqa to hormone therapy and radiation reduced the risk of metastasis or death by 58% in prostate-cancer patients at high risk of recurrence. Four-year metastasis-free sur ...
